Sanofi/€SAN
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Sanofi
Sanofi develops and markets drugs with a concentration in vaccines, immunology, oncology, cardiovascular disease, diabetes, and over-the-counter treatments. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing about 30% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
- Ticker
- €SAN
- Sector
- Health
- Primary listing
- PAR
- Employees
- 74,846
- Headquarters
- Paris, France
- Website
- www.sanofi.com
Sanofi Metrics
BasicAdvanced
€103B
24.97
€3.46
0.26
€4.12
4.77%
Price and volume
Market cap
€103B
Beta
0.26
52-week high
€90.90
52-week low
€71.25
Average daily volume
2.7M
Dividend rate
€4.12
Financial strength
Current ratio
1.116
Quick ratio
0.211
Long term debt to equity
0.222
Total debt to equity
0.271
Dividend payout ratio (TTM)
232.05%
Interest coverage (TTM)
18.00%
Profitability
EBITDA (TTM)
14,773
Gross margin (TTM)
74.29%
Net profit margin (TTM)
8.20%
Operating margin (TTM)
22.28%
Effective tax rate (TTM)
29.05%
Revenue per employee (TTM)
€680,000
Management effectiveness
Return on assets (TTM)
5.46%
Return on equity (TTM)
5.71%
Valuation
Price to earnings (TTM)
24.972
Price to revenue (TTM)
2.038
Price to book
1.42
Price to tangible book (TTM)
19.63
Price to free cash flow (TTM)
11.623
Free cash flow yield (TTM)
8.60%
Free cash flow per share (TTM)
7.428
Dividend yield (TTM)
4.77%
Forward dividend yield
4.77%
Growth
Revenue change (TTM)
11.00%
Earnings per share change (TTM)
-53.22%
3-year revenue growth (CAGR)
3.71%
10-year revenue growth (CAGR)
4.03%
3-year earnings per share growth (CAGR)
-21.74%
10-year earnings per share growth (CAGR)
0.59%
What the Analysts think about Sanofi
Analyst ratings (Buy, Hold, Sell) for Sanofi stock.
Analyst projections of the future price of Sanofi stock.
Bulls say / Bears say
Growth is beginning to broaden beyond Dupixent: sales from newer pharma launches rose 31.4% to €1.4 billion in Q3, led by ALTUVIIIO, Ayvakit and Rezurock. (Sanofi)
Vaccines were a weak spot in Q3, with sales down 6.6% to €3.2 billion; Sanofi expects the franchise to decline by a low-single-digit percentage for 2026. (Sanofi)
Data summarised monthly by Lightyear AI. Last updated on 4 Nov 2026.
Sanofi Financial Performance
Revenues and expenses
Sanofi Earnings Performance
Company profitability
Upcoming events
No upcoming events
Funds containing Sanofi
AllEURUSDGBP
Fund name | Fund size | €SAN weighting |
|---|---|---|
Amundi CAC 40€C40 | €999M | 6.03% |
iShares MSCI Europe Health Care Sector£ESIH | €890M | 5.25% |
iShares MSCI Europe Health Care Sector€ESIH | €890M | 5.25% |
iShares STOXX Europe 600 Health Care€EXV4 | €709M | 5.14% |
iShares Edge MSCI Europe Value Factor€CEMS | €2.6B | 4.67% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.